Tolgabide
From Wikipedia, the free encyclopedia
 |
|
|---|---|
| Systematic (IUPAC) name | |
| 4-{[(Z)-(3-chloro-5-methyl-6-oxocyclohexa-2,4-dien-1-ylidene)(4-chlorophenyl)methyl]amino}butanamide | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | Uncontrolled |
| Routes | ? |
| Identifiers | |
| CAS number | 86914-11-6 |
| ATC code | None |
| PubChem | CID 5748792 |
| ChemSpider | 4678139 |
| UNII | 0L55QF645F  |
| KEGG | D06181 |
| Chemical data | |
| Formula | C18H18Cl2N2O2 |
| Mol. mass | 365.25 g/mol |
|
|
Tolgabide (SL-81.0142) is a drug which was patented by Synthélabo as an anticonvulsant but was never marketed.[1] It is an analogue of progabide and acts similarly to it as a prodrug of GABA, and therefore as an indirect agonist of the GABA receptors.[1][2]
See also [edit]
References [edit]
- ^ a b David J. Triggle (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. ISBN 0-412-46630-9.
- ^ "The use of common stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances". 2002.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
